01761nas a2200277   4500000000100000008004100001260001300042653003100055653001300086653001200099653001100111653001100122653001200133653000900145653002800154653002300182100001600205700001300221700001600234245011400250856004100364300001100405490000700416520104600423022001401469       1986                            d  c1986 Dec10aAmbulatory Care Facilities10aCreatine10aDapsone10aFemale10aHumans10aleprosy10aMale10aMonitoring, Physiologic10aPatient Compliance1 aFischer J H1 aWest D P1 aWorobec S M00aEvaluation of a continual compliance monitoring program for dapsone in an outpatient Hansen's disease clinic.  uhttp://ila.ilsl.br/pdfs/v54n4a03.pdf  a517-240 v543 a<p>Guidelines for the assessment of patient compliance to dapsone were developed and evaluated. The urinary dapsone-to-creatinine (D/C) ratio following standardization by dose, ideal body weight, and time since last dose was used for assessment of compliance. Compliance standards were established in 12 patients of known compliance and confirmed prospectively in nine inpatients on 14 occasions. Compliance increased significantly among outpatients (N = 30) attending the University of Illinois Hansen's Disease Clinic from 47% at base line to 73% at 6 months and 80% at 18 months after establishing the monitoring program. In a subgroup of 18 patients, a similar increase in compliance was observed from 50% to 80%. A good therapeutic response was seen in the subgroup patients who were compliant. A poor therapeutic response was seen in the consistently noncompliant patients. These results demonstrate that use of a continual compliance monitoring program can improve patient drug compliance in an outpatient Hansen's disease clinic.</p>  a0148-916X